Evolving Concepts in Anterior Segment Outcomes: Comanaging Premium IOL Patients Video Interview

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

Marc R. Bloomensetin, OD, FAAO
Schwartz Laser Eye Center
Scottsdale, Arizona

Justin Schweitzer, OD, FAAO
Vance Thompson Vision
Sioux Falls, South Dakota

DISCLOSURE POLICY

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Marc R. Bloomenstein, OD, FAAO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision, Novartis, OcuSoft, Reichert, and Sun. Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision, Novartis, and Sun Pharma. Research/Grant Support: Allergan. Stock/Shareholder: Tearlab.

Justin Schweitzer, OD, FAAO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Aerie, Alcon, Allergan, Bausch + Lomb, EyePoint, Glaukos, Horizon, Johnson & Johnson Vision, Ocular Therapeutix, Quidel, Reichert, Sight Sciences, and Sun Pharma. Speaker’s Bureau:  Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, and Johnson & Johnson Vision.Stock/Shareholder:Equinox.

EDITORIAL DISCLOSURES

Erin K. Fletcher, MIT, director of compliance and education; Evolve; and Kate Fehlhaber, PhD, writer, have no financial relationships with commercial interests.